Table 1.

Studies in patients with MDS with BMF undergoing BM transplantation

Reference	Patients (N)	Patients with fibrosis, N (%)	OS	AML transformation	3-yr RFS	Engraftment (day)
Wang, et al. 2021 [21]	239 (MDS + MDS-AML)	MF-1 81 (33.9) MF-2/3 37 (15.5)	3-yr OS rate 72% vs. 67.5% vs. 41.3% (P = 0.018)	MF-2/3 vs. MF-1 vs. MF-0 8.8% vs. 39.9% vs. 50%, P = 0.028	72.8% vs. 68.8% vs. 44.8%; P = 0.018	Neutrophils, 13 vs. 13 vs. 14; P = 0.031 Platelets, 17 vs. 17.5 vs. 20.5; P = 0.05
Scott, et al. 2007 [34]	471	113	HR, 1.21; P = 0.16			Platelets, 17 vs. 28; P < 0.0001
Kroger, et al. 2011 [18]	721	MF-1/2 199 MF-3 39	HR, 1.13 vs. 1.94; P = 0.002		HR 1.13 vs. 1.88 (P = 0.003)	Platelets, 16 vs. 17 vs. 20; P = 0.002

Abbreviations: BM, bone marrow; BMF, bone marrow fibrosis; OS, overall survival; AML, acute myeloid leukemia; RFS, relapse free survival; MDS, myelodysplastic syndrome; MF-1/2/3, BMF grade 1/2/3: HR, hazard ratio.